Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

281 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR.
Assaad S, Avrillon V, Fournier ML, Mastroianni B, Russias B, Swalduz A, Cassier P, Eberst L, Steineur MP, Kazes M, Perol M, Michallet AS, Rey P, Erena-Penet AS, Morel A, Brahmi M, Dufresne A, Tredan O, Chvetzoff G, Fayette J, de la Fouchardiere C, Ray-Coquard I, Bachelot T, Saintigny P, Tabutin M, Dupré A, Nicolas-Virelizier E, Belhabri A, Roux PE, Fuhrmann C, Pilleul F, Basle A, Bouhamama A, Galvez C, Herr AL, Gautier J, Chabaud S, Zrounba P, Perol D, Blay JY. Assaad S, et al. Among authors: perol d, perol m. Eur J Cancer. 2020 Aug;135:251-259. doi: 10.1016/j.ejca.2020.05.028. Epub 2020 Jun 7. Eur J Cancer. 2020. PMID: 32540204 Free PMC article.
Early variations of circulating interleukin-6 and interleukin-10 levels during thoracic radiotherapy are predictive for radiation pneumonitis.
Arpin D, Perol D, Blay JY, Falchero L, Claude L, Vuillermoz-Blas S, Martel-Lafay I, Ginestet C, Alberti L, Nosov D, Etienne-Mastroianni B, Cottin V, Perol M, Guerin JC, Cordier JF, Carrie C. Arpin D, et al. Among authors: perol d, perol m. J Clin Oncol. 2005 Dec 1;23(34):8748-56. doi: 10.1200/JCO.2005.01.7145. J Clin Oncol. 2005. PMID: 16314635 Clinical Trial.
Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Bylicki O, Ferlay C, Chouaid C, Lavolé A, Barlési F, Dubos C, Westeel V, Créquit J, Corre R, Vergnenègre A, Monnet I, Le Caer H, Fournel P, Vaylet F, Falchero L, Poudenx M, Linard P, Pérol D, Zalcman G, Pérol M. Bylicki O, et al. Among authors: perol d, perol m. J Thorac Oncol. 2013 Jul;8(7):906-14. doi: 10.1097/JTO.0b013e31828cb505. J Thorac Oncol. 2013. PMID: 23591160 Free article. Clinical Trial.
Reply to N. Singh et al.
Pérol M, Pérol D, Chouaid C. Pérol M, et al. Among authors: perol d. J Clin Oncol. 2013 Mar 20;31(9):1251-2. doi: 10.1200/JCO.2012.47.8248. J Clin Oncol. 2013. PMID: 23616988 No abstract available.
281 results